10 results
Primary ObjectiveThe primary objective is to assess the efficacy and safety of rivaroxaban compared with placebo in the prevention of symptomatic venous thromboembolism (VTE) and VTE-related death posthospital discharge in high-risk, medically ill…
1. To test feasibility of mannitol inhalations in a Dutch pulmonary out-patient clinic.2. To compare time and costs involved in measuring airways hyperresponsiveness by methacholine to mannitol
1. To test feasibility of mannitol inhalations in a Dutch pulmonary out-patient clinic.2. To compare time and costs involved in measuring airways hyperresponsiveness by methacholine to mannitol
Aim of this study is to compare the effects of mannitol and HS in equimolar concentrations on cerebral blood flow, cerebral oxygenation, metabolism and inflammation in patients with severe TBI.
What is the correlation between change in Mannitol PD15 (provoking dose of mannitol to cause a >= 15% fall in FEV1 ) 6h after a single dose of beclomethasone and after 4 weeks of treatment with beclomethasone?
To assess whether a rivaroxaban-based anticoagulation strategy, following successful TAVR, compared to an antiplatelet-based strategy, is superior in reducing death or first thromboembolic events (DTE).To assess the primary bleeding events (PBE) of…
The primary objective of the study is to descriptively characterize the single-dose and steadystatePharmacokinetics (PK) of diacerein (if quantifiable) and its active metabolite, rhein, after topical application of CCP-020 (diacerein 1% ointment)…
to study the anti-tumor effect of cannabis oil (THC10% / CBD5%) in untreatable advanced HCC patients based on imaging using RECIST and modified RECIST (mRECIST) criteria
Patients with splanchnic vein thrombosis are at increased risk of recurrent VTE and bleeding. Routine anticoagulation with unfractionated heparin or low molecular weight heparin followed by warfarin is recommended in this setting, but limited data…
The primary objective of this study is to evaluate the long-term safety and tolerability of Diacerein 1% Ointment for 2 treatment cycles in subjects with EBS that were previously enrolled in studies CCP-020-301 or CCP-020-101.